Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142571 · ClinicalTrials.gov registry record · Phase 3
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
A Phase 3 study of Sarcoma, Soft Tissue, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00142571 is a Phase 3 study of Sarcoma, Soft Tissue that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 120 participants, above the 50-participant average among 4 other Sarcoma, Soft Tissue trials with a reported enrollment target (140% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00142571, a Phase 3 study of Sarcoma, Soft Tissue, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142571
The ClinicalTrials.gov registry entry for NCT00142571 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 4 other Sarcoma, Soft Tissue trials with a reported enrollment target (140% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma, Soft Tissue appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00142571 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00142571 about?
NCT00142571 is a clinical study titled "Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma". The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.
What is the current status of trial NCT00142571?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2003-01. Estimated completion is 2007-09.
What conditions does trial NCT00142571 study?
This clinical trial studies the following conditions: Sarcoma, Soft Tissue.
What interventions are being tested in trial NCT00142571?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00142571?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142571 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma, Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma
COMPLETED
-
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.